Stock comparison
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GYRE
Gyre Therapeutics
Market cap
$587.78M
Sector
Healthcare
RPRX
Royalty Pharma
Market cap
$23.44B
Sector
Healthcare
Overall winner
Royalty Pharma RPRX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
| Strategy | GYRE | RPRX | Winner |
|---|---|---|---|
| Warren Buffett | 44D | 66C | RPRX |
| Benjamin Graham | 57D | 84A | RPRX |
| Philip Fisher | 60C | 65C | RPRX |
| Peter Lynch | 47D | 60C | RPRX |
| Joel Greenblatt | 44D | 40D | GYRE |
| Charlie Munger | 49D | 68D | RPRX |
| Terry Smith | 50C | 58D | RPRX |
| Metric | GYRE | RPRX |
|---|---|---|
| Market cap | $587.78M | $23.44B |
| P/E (TTM) | - | 27.6x |
| EV/EBIT | 49.6x | 19.9x |
| ROIC (TTM) | 0.43% | 8.43% |
| Gross margin | 95.09% | 99.95% |
| Net margin | -5.37% | 33.91% |
| Revenue CAGR 5y | 99.65% | 0.96% |
| EPS CAGR 5y | - | 11.83% |
| Debt / Equity | 0.0x | 1.3x |
| Dividend yield | 0.0% | 1.72% |
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GYRE leads on
RPRX leads on
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.